Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | HLA-A | P04439 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8287187 | 0.91 | KCNH2 (0.43) | KCNH2NR4A2SSTR5LMNAGAA | |
| SCHEMBL4776300 | 0.91 | KCNH2 (0.43) | KCNH2NR4A2SSTR5NPY1RLMNA | |
| Jnj 2408068 SCHEMBL29427933 | 0.90 | KCNH2 (0.42) | KCNH2NR4A2SSTR5LMNAGAA | |
| Jnj 2408068 SCHEMBL3890162 | 0.90 | KCNH2 (0.42) | KCNH2NR4A2SSTR5LMNAGAA | |
| Jnj 2408068 SCHEMBL29365461 | 0.90 | KCNH2 (0.42) | KCNH2NR4A2SSTR5LMNAGAA | |
| SCHEMBL8289247 | 0.90 | KCNH2 (0.44) | KCNH2NR4A2SSTR5NPY1RLMNA | |
| Jnj 2408068 SCHEMBL29623997 | 0.90 | KCNH2 (0.42) | KCNH2NR4A2SSTR5LMNAGAA | |
| Jnj 2408068 SCHEMBL4980538 | 0.89 | KCNH2 (0.42) | KCNH2NR4A2SSTR5LMNAGAA | |
| SCHEMBL8287092 | 0.88 | KCNH2 (0.47) | KCNH2NR4A2SSTR5NPY1RUSP2 | |
| SCHEMBL8287095 | 0.87 | SSTR5 (0.36) | KCNH2NR4A2SSTR5LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1723136-B1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2011-03-09 | — | — | EP | disclosed |
| EP-1723136-B1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2011-03-09 | — | — | EP | disclosed |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-06-19 | — | — | US | disclosed |
| US-7355051-B2 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2008-04-08 | — | — | US | disclosed |
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-04-26 | — | — | US | disclosed |
| EP-1723136-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Tibotec Pharmaceuticals Ltd. (IE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005058873-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093659-A1 | Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication | NQO2, NOX1, NOX3 | KCNH2 347/4885NR4A2 388/4885SSTR5 4287/4885 |
| US-20080146613-A1 | PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | NQO2, NOX3, NOX1 | KCNH2 487/4885NR4A2 311/4885SSTR5 4354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.